ANSWER: C

Rationale:

The fully reversible shimmering zigzag lines (fortification spectra) and a drifting central scotoma that precede the headache and resolve as the head pain begins are textbook visual aura of migraine with aura. The pharmacological significance is decisive: migraine with aura is a WHO MEC Category 4 absolute contraindication to all estrogen-containing methods (combined oral contraceptive, patch, ring), because ethinyl estradiol (EE) produces a multiplicative — not merely additive — increase in ischemic stroke risk when combined with the baseline elevated stroke risk of migraine with aura. Recognizing the aura is therefore the trigger to discontinue her combined pill. Her normal blood pressure, nonsmoking status, and absence of thrombosis history do not mitigate this, because the Category 4 status is conferred by the aura itself.

• Option A: Option A is incorrect because these are not tension-type headache symptoms — tension headaches do not have a preceding reversible visual aura of zigzag lines and scotoma; mischaracterizing them would leave her on a contraindicated estrogen method.
• Option B: Option B is incorrect because idiopathic intracranial hypertension presents with headache, visual obscurations, and papilledema rather than a discrete reversible visual aura preceding the headache, and the specific contraceptive concern here is the estrogen-mediated stroke risk of migraine with aura, not a generic intracranial pressure issue.
• Option D: Option D is incorrect because fully reversible visual aura preceding a typical migraine headache is not a transient ischemic attack or completed stroke — there are no persistent deficits, and the management is to remove the estrogen contraindication, not to anticoagulate.
• Option E: Option E is incorrect because the symptoms described are precisely migraine with aura, which does carry a Category 4 contraindication to combined hormonal methods; labeling them a benign ocular migraine without contraindication would be clinically dangerous.

ANSWER: A

Rationale:

The correct action is to transition her to a progestin-only method — the LNG-IUD, etonogestrel implant, progestin-only pill, or DMPA — all of which contain no ethinyl estradiol (EE) and are WHO MEC Category 1 or 2 in migraine with aura. Because the Category 4 contraindication in migraine with aura is driven entirely by the estrogen component and its multiplicative effect on arterial stroke risk, removing EE eliminates the relevant risk while preserving effective hormonal contraception. A LARC such as the LNG-IUD or implant additionally offers the highest efficacy.

• Option B: Option B is incorrect because the combined vaginal ring contains ethinyl estradiol absorbed systemically and is Category 4 in migraine with aura just like the oral pill — vaginal delivery does not avoid the systemic estrogen-mediated stroke risk.
• Option C: Option C is incorrect because the combined patch delivers systemic ethinyl estradiol and is also Category 4 in migraine with aura — transdermal estrogen is not exempt from the restriction, since the arterial risk arises from systemic EE regardless of route.
• Option D: Option D is incorrect because no ethinyl estradiol dose is acceptable in migraine with aura — the Category 4 designation applies to any EE-containing method regardless of dose, because even low-dose EE confers the arterial stroke risk amplification.
• Option E: Option E is incorrect because hormonal contraception is not entirely off-limits for her — progestin-only methods are safe (Category 1 or 2) in migraine with aura, so restricting her to barrier methods alone would needlessly deny her reliable hormonal options.

ANSWER: D

Rationale:

The arterial stroke risk that makes combined methods Category 4 in migraine with aura is driven specifically by the ethinyl estradiol (EE) component. EE promotes hepatic synthesis of coagulation factors, reduces activated protein C sensitivity, and enhances platelet activation — a procoagulant, prothrombotic profile that, layered on the baseline elevated arterial risk of migraine with aura, multiplies stroke risk. Progestin-only methods such as the LNG-IUD contain no EE and therefore do not produce this estrogen-mediated arterial effect, which is the pharmacological reason they are safe (Category 1 or 2) in migraine with aura. The key teaching point is that "contains a hormone" is not the relevant distinction — the relevant distinction is the presence or absence of the estrogen component.

• Option A: Option A is incorrect because progestins do not function as anticoagulants and do not lower stroke risk below baseline — the safety of the LNG-IUD comes from the absence of the EE-mediated procoagulant effect, not from any active blood-thinning property.
• Option B: Option B is incorrect because the LNG-IUD does contain a hormone (levonorgestrel) and works through local progestogenic effects on the endometrium and cervical mucus, not purely by mechanical irritation; the non-hormonal mechanical-irritation device is the copper IUD.
• Option C: Option C is incorrect because levonorgestrel is not converted into an anti-inflammatory cerebroprotective metabolite — there is no such protective conversion; the safety of the LNG-IUD derives from the absence of ethinyl estradiol, not from a protective levonorgestrel metabolite.
• Option E: Option E is incorrect because the LNG-IUD does produce low systemic levonorgestrel levels (approximately 150 to 200 picograms per milliliter for the 52 mg device) — it is not true that no hormone reaches the circulation; its safety comes from the absence of EE rather than from a complete absence of systemic progestin.

ANSWER: B

Rationale:

The 52 mg LNG-IUD works predominantly through local progestogenic effects within the uterus: high local levonorgestrel concentrations produce endometrial decidualization followed by glandular atrophy, making the endometrium unsuitable for implantation, and they thicken cervical mucus to an impenetrable state. Although the device suppresses ovulation in roughly 50% of cycles in the first year, this proportion falls below 25% by year 5 — meaning that for most of its lifespan ovulation continues, and the local endometrial and cervical effects are the dominant contraceptive mechanism. This local action, achieved at systemic levonorgestrel levels far below those of oral levonorgestrel pills, also explains the device's minimal systemic side effects and its safety in conditions like migraine with aura.

• Option A: Option A is incorrect because the LNG-IUD does not reliably suppress ovulation in every cycle — ovulation suppression falls below 25% of cycles by year 5, so exclusive reliance on systemic ovulation suppression is not its mechanism.
• Option C: Option C is incorrect because the LNG-IUD does not release copper or work by copper ion toxicity — that is the mechanism of the copper IUD; the LNG-IUD works by local progestogenic effects.
• Option D: Option D is incorrect because the LNG-IUD does not work by causing heavy bleeding that flushes the cavity — on the contrary, it typically reduces menstrual bleeding through endometrial atrophy, and its mechanism is local progestogenic suppression of the endometrium, not mechanical flushing.
• Option E: Option E is incorrect because systemic levonorgestrel levels with the LNG-IUD are far lower than those produced by oral levonorgestrel pills — this is precisely why systemic effects are minimal — and it does not rely on systemic ovulation suppression equivalent to combined pills.

ANSWER: B

Rationale:

This patient's breakthrough seizures, occurring weeks after starting an ethinyl estradiol (EE)-containing combined pill in a previously well-controlled patient with a documented drop in lamotrigine level, are the classic presentation of the EE-lamotrigine interaction. EE is a potent inducer of UGT1A4, the enzyme responsible for glucuronidation (the primary inactivation pathway) of lamotrigine. EE-driven UGT1A4 induction accelerates lamotrigine clearance and reduces its plasma concentration by 40 to 65% within 2 to 4 weeks of starting the pill, dropping the patient below her therapeutic threshold and precipitating breakthrough seizures. The documented fall in her lamotrigine level confirms the mechanism.

• Option A: Option A is incorrect because the combined pill does have a substantial pharmacokinetic effect on lamotrigine through UGT1A4 induction — the documented drop in lamotrigine level and the temporal relationship to starting the pill point directly to the interaction, not to spontaneous worsening.
• Option C: Option C is incorrect because it inverts the direction of the interaction — it is ethinyl estradiol that induces lamotrigine metabolism, not lamotrigine that induces EE metabolism; and the mechanism of breakthrough seizures is the documented drop in lamotrigine level, not estrogen withdrawal.
• Option D: Option D is incorrect because the interaction is not a plasma protein binding displacement by levonorgestrel — it is enzymatic induction of UGT1A4 by ethinyl estradiol; protein-binding displacement is not the mechanism, and her total lamotrigine level fell because of accelerated glucuronidation.
• Option E: Option E is incorrect because her lamotrigine level fell rather than rose — the seizures are from subtherapeutic lamotrigine due to accelerated clearance, not from toxicity; lamotrigine toxicity would present with dizziness, diplopia, and ataxia, not breakthrough seizures, and would be associated with elevated rather than reduced levels.

ANSWER: E

Rationale:

This question tests the reversibility and bidirectionality of the EE-lamotrigine interaction. If the lamotrigine dose were increased to compensate for the lower levels caused by EE-induced UGT1A4 induction while the patient remained on a cyclic 21/7 pill, a predictable problem would arise during the 7-day hormone-free interval. During those days, EE is withdrawn, UGT1A4 induction reverses toward baseline, and lamotrigine clearance slows. With the now-increased lamotrigine dose and reduced clearance, lamotrigine levels would rebound into the toxic range, producing dose-related toxicity — dizziness, diplopia, and ataxia — each month during the pill-free week. This cyclic toxicity is exactly why simply increasing the lamotrigine dose is not a good solution and why avoiding EE-containing methods (using a progestin-only method instead) is preferred.

• Option A: Option A is incorrect because the hormone-free interval does affect lamotrigine pharmacokinetics — the withdrawal of EE during those days reverses UGT1A4 induction and slows lamotrigine clearance, so it is not pharmacokinetically neutral.
• Option B: Option B is incorrect because lamotrigine levels rise, not fall, during the hormone-free interval — the removal of the inducing EE slows lamotrigine clearance, so the risk during the pill-free week is toxicity from rising levels, not worsening subtherapeutic seizures.
• Option C: Option C is incorrect because the hormone-free interval does not permanently reset UGT1A4 — the induction reverses transiently during the pill-free days and is re-established when active pills resume, producing recurring monthly fluctuation rather than a permanent new baseline.
• Option D: Option D is incorrect because the predominant problem during the hormone-free interval would be lamotrigine toxicity from rebounding levels (dizziness, diplopia, ataxia), not estrogen-withdrawal headaches; the dose increase plus slowed clearance drives measurable lamotrigine elevation, which is a distinct and identifiable toxicity.

ANSWER: A

Rationale:

The optimal solution is to eliminate the source of the fluctuation: switch her to a progestin-only method such as the LNG-IUD or etonogestrel implant. These methods contain no ethinyl estradiol (EE), so they do not induce UGT1A4 and do not lower or destabilize lamotrigine levels — the interaction is removed entirely rather than managed by repeated dose adjustments. A LARC such as the LNG-IUD or implant additionally provides the most reliable contraception, which is important in a woman whose pregnancy would carry its own seizure-medication considerations. This is the recommended approach for women stabilized on lamotrigine.

• Option B: Option B is incorrect because switching to a continuous combined regimen would increase total EE exposure and further lower lamotrigine levels — it would worsen the interaction, not resolve it, and would still carry the EE-driven UGT1A4 induction.
• Option C: Option C is incorrect because a higher EE dose would intensify UGT1A4 induction and lower lamotrigine further; making the interaction "more predictable" by increasing EE is not a sound strategy and increases both the seizure risk and estrogen-related risks.
• Option D: Option D is incorrect because discontinuing effective lamotrigine monotherapy in a woman who was seizure-free for 2 years would be dangerous and inappropriate — the combined pill is not an antiepileptic and would not control her epilepsy; the goal is to keep her stable lamotrigine and remove the interfering estrogen.
• Option E: Option E is incorrect because adding a second enzyme-inducing antiepileptic drug would further induce lamotrigine metabolism and lower its levels, compounding the problem rather than stabilizing it, and would expose her to additional medication risks without benefit.

ANSWER: D

Rationale:

This question contrasts the lamotrigine scenario (where the concern is EE lowering lamotrigine) with the enzyme-inducer scenario (where the concern is induction lowering contraceptive steroid levels). With a strong CYP3A4 inducer like carbamazepine, the levonorgestrel-releasing intrauterine device (LNG-IUD) remains WHO MEC Category 1 (no restriction) because its contraceptive effect depends on extremely high local levonorgestrel concentrations within the endometrium and cervix — hundreds of times higher than systemic plasma levels. Even though carbamazepine accelerates systemic levonorgestrel metabolism, the local intrauterine concentrations that actually mediate contraception are unaffected by systemic enzyme induction. Because the mechanism is local rather than systemic, the LNG-IUD is uniquely protected.

• Option A: Option A is incorrect because a combined oral contraceptive is Category 3 with enzyme-inducing antiepileptic drugs — carbamazepine substantially reduces ethinyl estradiol and progestin levels, and the estrogen component does not offset the induction; it is compromised, not protected.
• Option B: Option B is incorrect because oral progestins are not unaffected by enzyme induction — the progestin-only pill depends on systemic progestin levels, which carbamazepine reduces through CYP3A4 induction, compromising its reliability.
• Option C: Option C is incorrect because the combined patch delivers ethinyl estradiol systemically, and transdermal delivery does not escape systemic CYP3A4 induction — the induced enzymes metabolize systemically absorbed EE regardless of the route, so the patch is also compromised.
• Option E: Option E is incorrect because the etonogestrel implant is not immune to CYP3A4 induction — its systemic etonogestrel levels can be reduced by strong inducers, and it is classified Category 2 to 3 (not Category 1) with enzyme-inducing antiepileptic drugs, with some guidance recommending against its use; only the LNG-IUD is Category 1.

ANSWER: A

Rationale:

This patient's contraceptive failure despite perfect adherence is explained by the paradoxical net effect of her ritonavir-boosted protease inhibitor regimen on ethinyl estradiol (EE). Although ritonavir is one of the most potent CYP3A4 inhibitors known and is used to boost protease inhibitor levels, its net effect on EE is a reduction in exposure of approximately 40 to 50%, because ritonavir induces UGT-mediated EE glucuronidation, and this induction of the alternative conjugation pathway outweighs the CYP3A4 inhibition. The resulting fall in EE levels compromised gonadotropin suppression and made her combined pill unreliable. This counterintuitive net direction — reduction, not elevation, of EE despite CYP3A4 inhibition — is the key teaching point.

• Option B: Option B is incorrect because ritonavir did not raise her ethinyl estradiol levels — its net effect is a reduction in EE exposure through UGT induction; there is no mechanism by which excessively high EE would suppress the contraceptive effect.
• Option C: Option C is incorrect because the protease inhibitor does not bind ethinyl estradiol in the gut and prevent its absorption — the interaction is a metabolic one (UGT induction accelerating EE glucuronidation), not a physical absorption-blocking effect.
• Option D: Option D is incorrect because ritonavir did not selectively raise progestin while leaving EE unchanged — its net effect is to reduce EE (and it affects progestins as well); the failure reflects reduced EE exposure, not a selective progestin increase.
• Option E: Option E is incorrect because her antiretroviral therapy did have a substantial effect on the pill — the ritonavir-boosted regimen reduced EE exposure by 40 to 50% — so attributing the failure to unrecognized missed doses ignores a well-documented and clinically important drug interaction.

ANSWER: C

Rationale:

An integrase strand-transfer inhibitor (INSTI) regimen — such as dolutegravir, raltegravir, or bictegravir — would allow a combined oral contraceptive to be reliable, because INSTIs do not meaningfully induce or inhibit the enzymes that metabolize ethinyl estradiol (EE) and progestins, leaving contraceptive steroid levels essentially unchanged. Where clinically appropriate from the HIV-treatment standpoint, switching from the ritonavir-boosted protease inhibitor to an INSTI-based regimen removes the EE-lowering interaction and restores combined-pill reliability. This makes the INSTI class the contraceptive-neutral choice for a woman who prioritizes reliable hormonal contraception.

• Option A: Option A is incorrect because efavirenz, a non-nucleoside reverse transcriptase inhibitor, is a potent CYP3A4 inducer that reduces EE and progestin levels by 40 to 60% — switching to efavirenz would not restore contraceptive reliability and would compromise it.
• Option B: Option B is incorrect because a different ritonavir-boosted protease inhibitor would carry the same UGT-induction-mediated reduction in EE exposure — the problem is the boosting and the class effect on EE glucuronidation, so switching within the boosted-PI class would not solve it.
• Option D: Option D is incorrect because cobicistat, like ritonavir, reduces EE exposure and renders combined hormonal methods unreliable — a cobicistat-boosted regimen would not be contraceptive-neutral.
• Option E: Option E is incorrect because rifabutin is an enzyme inducer (a less potent PXR agonist than rifampin but still clinically significant) that reduces contraceptive steroid levels — adding it would worsen, not resolve, the interaction.

ANSWER: E

Rationale:

When the antiretroviral regimen cannot be changed, the pharmacologically sound choice is a method whose efficacy does not depend on systemic contraceptive steroid levels. The LNG-IUD acts through high local levonorgestrel concentrations within the uterus, and the copper IUD acts through non-hormonal copper ion cytotoxicity to sperm — neither depends on maintaining systemic plasma steroid levels, so both are unaffected by the ritonavir-boosted regimen's reduction of ethinyl estradiol exposure. Both provide highly reliable, long-acting contraception independent of the drug interaction, making them the appropriate choice in this scenario.

• Option A: Option A is incorrect because increasing to a 50-microgram ethinyl estradiol pill is not a reliable or recommended way to overcome the antiretroviral interaction — it increases estrogen-related risks without dependable restoration of efficacy, and an interaction-independent method is the better solution.
• Option B: Option B is incorrect because oral progestins are not immune to the antiretroviral interaction — the progestin-only pill depends on systemic progestin levels, which can be affected by the regimen, so it is not fully protected; the interaction-independent methods are the IUDs.
• Option C: Option C is incorrect because the combined patch delivers ethinyl estradiol systemically and is subject to the same UGT-induction-mediated reduction in EE exposure as the oral pill — transdermal delivery does not escape the systemic interaction.
• Option D: Option D is incorrect because doubling the combined pill to two tablets daily is not an evidence-based or safe strategy to compensate for reduced ethinyl estradiol exposure — it increases estrogen-related risk and does not reliably restore contraceptive efficacy; an interaction-independent method is appropriate instead.

ANSWER: B

Rationale:

The unifying principle is that drug-interaction vulnerability is determined by whether a method's contraceptive effect depends on maintaining adequate systemic plasma steroid concentrations. Methods that rely on systemic levels — combined pills, the patch, the ring, the progestin-only pill, and to a lesser extent the etonogestrel implant — are vulnerable to enzyme inducers (and to net-EE-lowering regimens like boosted protease inhibitors) because reduced systemic levels compromise their mechanism. Methods whose effect is local (the LNG-IUD, via high intrauterine concentrations) or non-hormonal (the copper IUD, via copper ion cytotoxicity) are not vulnerable, because their efficacy does not depend on systemic steroid concentrations. This principle lets the patient understand past failures and anticipate future ones if her medications change.

• Option A: Option A is incorrect because the estrogen-versus-progestin distinction is not the sole determinant of interaction vulnerability — many progestin-containing methods (progestin-only pill, implant) are still vulnerable because they depend on systemic levels; the decisive factor is systemic-versus-local dependence, not hormone class.
• Option C: Option C is incorrect because route of administration alone does not determine protection — the patch and ring are non-oral yet still vulnerable because they deliver steroid systemically; what matters is whether the contraceptive effect depends on systemic levels, not merely whether the route is oral.
• Option D: Option D is incorrect because steroid half-life is not the determinant of interaction immunity — even long-half-life depot methods can be affected by induction, and the LNG-IUD's protection comes from its local site of action, not from a long systemic half-life.
• Option E: Option E is incorrect because hormonal methods are not all equally vulnerable — route and, more importantly, site of action (systemic versus local) make a decisive difference, which is precisely why the LNG-IUD remains reliable where systemically-dependent methods fail.

ANSWER: E

Rationale:

Three features of this case converge on the copper IUD. First, her BMI of 36 places her above the threshold (approximately BMI 35) at which oral levonorgestrel emergency contraception becomes unreliable due to subtherapeutic serum levonorgestrel concentrations. Second, she presents at 96 hours, beyond the practical 72-hour levonorgestrel window but still within the copper IUD's 5-day window. Third, she is near ovulation, when oral agents that work by delaying ovulation are most likely to fail. The copper IUD is the most effective emergency contraceptive available (failure rate below 0.1%), its copper ion cytotoxicity mechanism is entirely independent of body weight, and it provides reliable ongoing contraception, which she desires. It is clearly the best choice.

• Option A: Option A is incorrect because levonorgestrel 1.5 mg is unreliable at a BMI of 36 and has a practical window of 72 hours, not 120 hours — at 96 hours and at her BMI it is both outside its window and unreliable.
• Option B: Option B is incorrect because emergency contraception is still indicated at 96 hours — sperm survive up to 5 days, and the copper IUD can prevent pregnancy from intercourse up to 5 days before insertion; reassurance that conception is impossible would be wrong.
• Option C: Option C is incorrect because the Yuzpe regimen is less effective than the copper IUD and than dedicated levonorgestrel or ulipristal regimens, and it is not the most effective option at elevated BMI; it is largely of historical interest.
• Option D: Option D is incorrect because a double dose of levonorgestrel is not an evidence-based strategy to overcome high-BMI attenuation — there is no validated double-dose regimen that restores reliable efficacy at her BMI, and the copper IUD is the appropriate weight-independent solution.

ANSWER: B

Rationale:

If she declines the copper IUD and an oral agent must be used, ulipristal acetate (UPA) is preferred over levonorgestrel for two reasons that are both decisive in this patient. First, UPA is more weight-robust than levonorgestrel: levonorgestrel efficacy declines above approximately BMI 26 and becomes inadequate above approximately BMI 35, whereas UPA maintains superior efficacy at higher BMI categories. Second, because she is near ovulation, the LH surge may already have begun; UPA, as a selective progesterone receptor modulator, can still inhibit or delay follicular rupture after the surge has started, whereas levonorgestrel cannot. Both features favor UPA in a high-BMI woman near ovulation. (At her BMI even UPA shows some attenuation, which is why the copper IUD remains the most effective option, but among oral agents UPA is clearly preferred.)

• Option A: Option A is incorrect because it inverts both facts — levonorgestrel is less weight-robust than ulipristal acetate, and levonorgestrel does not work better near ovulation; it loses efficacy once the LH surge has begun, whereas UPA retains activity.
• Option C: Option C is incorrect because ulipristal acetate is not contraindicated in women with BMI above 30 — it is in fact the preferred oral agent at elevated BMI; the claim of a contraindication is wrong.
• Option D: Option D is incorrect because a combined oral contraceptive used as emergency contraception (the Yuzpe regimen) is less effective than dedicated agents and is not unaffected by BMI — it is not the preferred oral choice here.
• Option E: Option E is incorrect because oral emergency contraception, particularly ulipristal acetate, can still provide benefit at BMI above 35 even though efficacy is somewhat attenuated — the claim that no oral agent can work at all is too absolute, and UPA remains a reasonable option if she declines the copper IUD.

ANSWER: C

Rationale:

Because ulipristal acetate (UPA) is a partial progesterone receptor (PR) antagonist whose emergency contraceptive effect depends on its activity at the PR, starting a progestin-containing contraceptive too soon would introduce progestin that competes with UPA at the receptor and attenuates UPA's effect. Current FSRH guidance therefore recommends waiting approximately 5 days after UPA before starting a progestin-containing method (combined or progestin-only), and using a barrier method in the interim. This protects the efficacy of the UPA she just took. The interaction is a receptor-competition effect, not a permanent incompatibility — after the 5-day interval she can begin her ongoing method normally.

• Option A: Option A is incorrect because she should not start the progestin-only pill immediately, and taking an extra dose of ulipristal acetate is not indicated — starting a progestin too soon would undermine the UPA effect through receptor competition, the opposite of reinforcing it.
• Option B: Option B is incorrect because the incompatibility is not permanent — it is a transient receptor-competition issue that resolves after the recommended approximately 5-day interval, after which progestin-containing methods can be used normally.
• Option D: Option D is incorrect because there is a pharmacological interaction between ulipristal acetate and progestins — starting a progestin too soon attenuates UPA's effect via progesterone receptor competition, so immediate initiation is not appropriate.
• Option E: Option E is incorrect because starting a combined estrogen-progestin pill immediately is also problematic — the relevant interaction is at the progesterone receptor, and combined pills contain a progestin that would likewise compete with UPA; it is not true that only progestin-only pills interact, so the 5-day wait applies to combined methods as well.

ANSWER: A

Rationale:

Levonorgestrel emergency contraception works by a pre-ovulatory mechanism: it suppresses the LH surge before it peaks and delays follicular rupture. It has no consistent effect on post-fertilization events and is ineffective once ovulation is imminent or has already occurred. In a woman presenting near ovulation — as this patient was, around day 13 — the LH surge may already be underway, and at that point levonorgestrel can no longer reliably prevent ovulation. This mechanistic limitation makes levonorgestrel especially unsuitable in her situation, compounding the separate BMI-related attenuation. It also explains why ulipristal acetate (which retains post-LH-surge activity) and the copper IUD (which works independently of ovulation) are the better choices near ovulation.

• Option B: Option B is incorrect because levonorgestrel emergency contraception does not work by preventing implantation — its mechanism is pre-ovulatory LH-surge suppression, and it is ineffective after ovulation has occurred, so it would not have worked well in a woman near or past ovulation.
• Option C: Option C is incorrect because levonorgestrel emergency contraception does not physically block the fallopian tubes — that is not its mechanism; it acts at the hypothalamic-pituitary level to suppress the LH surge.
• Option D: Option D is incorrect because levonorgestrel emergency contraception does not work by cervical mucus thickening as its emergency mechanism — at the 1.5 mg single dose its emergency effect is pre-ovulatory LH-surge suppression, and it is not fully effective regardless of cycle position.
• Option E: Option E is incorrect because levonorgestrel is not a selective progesterone receptor modulator and does not inhibit follicular rupture after the LH surge — that post-surge capability belongs to ulipristal acetate; levonorgestrel loses efficacy once the surge has begun, so cycle position is highly relevant to its efficacy.

ANSWER: D

Rationale:

In breastfeeding women, combined hormonal methods are WHO MEC Category 4 during the first 6 weeks postpartum. Two pharmacological concerns drive this. First, the early postpartum period is a recognized hypercoagulable, elevated-VTE-risk state, and ethinyl estradiol (EE) adds further venous thrombotic risk by promoting hepatic coagulation factor synthesis. Second, there is concern about neonatal exposure to exogenous estrogen through breast milk during a period of neonatal hepatic enzyme immaturity. At 4 weeks postpartum and breastfeeding, she falls within this Category 4 window, so a progestin-only method (progestin-only pill, etonogestrel implant, or DMPA) is the preferred and appropriate choice now. Her lack of thrombosis history does not change the Category 4 status, which applies to early-postpartum breastfeeding women as a group.

• Option A: Option A is incorrect because combined methods are not Category 1 at 4 weeks postpartum — the early postpartum state raises, not lowers, thrombotic risk, so EE-containing methods are contraindicated, not freely usable.
• Option B: Option B is incorrect because combined methods are Category 4, not Category 2, in breastfeeding women in the first 6 weeks postpartum — the absence of a thrombosis history does not downgrade the category, because the elevated postpartum VTE risk applies generally.
• Option C: Option C is incorrect because exclusive breastfeeding does not provide indefinite, complete protection — lactational amenorrhea requires strict criteria and a limited time window, and she is about to resume intercourse and wants contraception, so advising no method would be inappropriate.
• Option E: Option E is incorrect because not all hormonal contraception is contraindicated during breastfeeding — progestin-only methods are appropriate and safe during lactation; only the estrogen-containing combined methods are Category 4 in the early postpartum period.

ANSWER: A

Rationale:

DMPA is distinctive among reversible contraceptives in producing a substantially delayed return to fertility: the median time to resumption of ovulation is approximately 9 to 10 months after the last injection, with occasional delays up to 18 months. This delay is a pharmacokinetic property of the depot formulation — medroxyprogesterone acetate is released slowly from the injection site and continues to suppress the hypothalamic-pituitary-ovarian axis well after the contraceptive interval — and it is independent of how long DMPA has been used. Because she hopes to conceive in about a year, she should be counseled about this delay and may wish either to discontinue DMPA well in advance of her target conception date or to choose an alternative method (such as an implant or IUD) with a faster return to fertility after removal.

• Option B: Option B is incorrect because DMPA does delay return to fertility — ovulation does not resume within days; the depot pharmacokinetics produce a median delay of 9 to 10 months, so she could not conceive immediately upon stopping.
• Option C: Option C is incorrect because DMPA does not cause permanent infertility — fertility returns in all users after the depot effect wanes; the issue is a reversible delay, not permanent infertility.
• Option D: Option D is incorrect because the delay is not proportional to the number of injections — it is a pharmacokinetic property of the depot that applies even after a single injection, so a single dose can still delay conception.
• Option E: Option E is incorrect because DMPA's return to fertility is not identical to that of combined oral contraceptives — combined pills allow fertility return within about 4 to 6 weeks, whereas DMPA's median is 9 to 10 months, a substantial difference relevant to her planning.

ANSWER: B

Rationale:

The etonogestrel implant and the LNG-IUD are both progestin-only methods that are safe during breastfeeding and are associated with a rapid return to fertility after removal — ovulation typically resumes within a few weeks of removing the implant or IUD. This contrasts sharply with DMPA's prolonged delay (median 9 to 10 months). For a woman who is breastfeeding (needing a progestin-only method) and who plans to conceive in about a year, a LARC such as the implant or LNG-IUD is an excellent fit: it provides reliable contraception now and allows prompt fertility return when she is ready to conceive.

• Option A: Option A is incorrect because a combined oral contraceptive is not safe in early breastfeeding — it is Category 4 in the first 6 weeks postpartum in breastfeeding women — so despite its prompt return to fertility, it is not an appropriate choice for her at this time.
• Option C: Option C is incorrect because stopping DMPA 3 months before conception does not fully eliminate the return-to-fertility delay — the median delay is 9 to 10 months and is not reliably abolished by a 3-month lead time, so this would not dependably allow conception on her timeline.
• Option D: Option D is incorrect because the implant and LNG-IUD do not share DMPA's prolonged delay — both have a rapid return to fertility after removal; the norethindrone minipill also allows prompt return, but it is not the only progestin-only method that does.
• Option E: Option E is incorrect because progestin-only methods other than DMPA (the implant, LNG-IUD, and progestin-only pills) do allow a rapid return to fertility — she is not limited to accepting the DMPA delay or using barrier methods only.

ANSWER: E

Rationale:

The Category 4 restriction on combined hormonal methods in the early postpartum period is driven by the time-limited, elevated venous thromboembolism (VTE) risk of the puerperium, which is highest immediately after delivery and declines over the following weeks. As she moves further from delivery, this venous thrombotic risk falls and her eligibility for combined methods improves. The restriction is specifically tied to the early postpartum window (the first 6 weeks in breastfeeding women). However, while she continues breastfeeding, a progestin-only method generally remains preferred, and any later transition to a combined method should still account for her breastfeeding status and confirm the absence of other contraindications (such as migraine with aura or hypertension). This reflects an accurate understanding of how postpartum eligibility evolves over time rather than being fixed.

• Option A: Option A is incorrect because the Category 4 restriction does not apply only on the day of delivery — it extends through the early postpartum period (the first 6 weeks in breastfeeding women), reflecting the duration of elevated VTE risk, so she cannot switch at any time in that window.
• Option B: Option B is incorrect because she is not permanently barred from combined methods after giving birth — eligibility improves as she moves beyond the early postpartum period; the restriction is time-limited, not permanent.
• Option C: Option C is incorrect because combined methods do not become Category 1 immediately at 2 weeks postpartum regardless of breastfeeding — in breastfeeding women the Category 4 restriction extends through the first 6 weeks, so a 2-week blanket Category 1 is incorrect.
• Option D: Option D is incorrect because blood pressure is not the only determinant of combined-method eligibility — the postpartum VTE risk timeline and breastfeeding status are the key factors here, and her eligibility does improve over time as the puerperal thrombotic risk declines.

ANSWER: C

Rationale:

Current breast cancer is the key exception to the usual pattern in which progestin-only methods are safer than combined methods. Current breast cancer is a WHO MEC Category 4 absolute contraindication for all hormonal methods — both estrogen-containing and progestin-only — because hormone receptor-positive tumors express both estrogen and progesterone receptors, and exogenous hormones of any class risk stimulating tumor growth or recurrence. The relative's belief that "progestin methods are fine for breast cancer" is therefore incorrect in this setting. The appropriate recommendation is a non-hormonal method, and the copper intrauterine device is the preferred choice: it is highly effective, provides reliable ongoing contraception, and is entirely non-hormonal, working through copper ion cytotoxicity to sperm. Barrier methods and sterilization are other non-hormonal options.

• Option A: Option A is incorrect because progestin-only methods are not safe in current breast cancer — they are Category 4, the same as combined methods, because progesterone receptors in the tumor make progestins a growth risk; the belief that only estrogen is a problem is the specific misconception this case targets.
• Option B: Option B is incorrect because the LNG-IUD, despite its predominantly local action, is still Category 4 in current breast cancer — its low but real systemic levonorgestrel exposure is not considered safe in the presence of an active hormone-sensitive malignancy.
• Option D: Option D is incorrect because no ethinyl estradiol dose is acceptable in current breast cancer — combined methods are Category 4 regardless of dose, with no safe "below threshold" estrogen exposure in an active hormone-sensitive tumor.
• Option E: Option E is incorrect because depot medroxyprogesterone acetate is a systemic progestin and is Category 4 in current breast cancer — its depot delivery does not make it safe, because any systemic progestin exposure risks stimulating a progesterone-receptor-positive tumor.

ANSWER: D

Rationale:

Hormone receptor-positive breast tumors commonly express progesterone receptors in addition to estrogen receptors. Exogenous progestins can act as growth signals through these progesterone receptors, risking stimulation of tumor growth or recurrence. This is the pharmacological reason progestin-only methods are WHO MEC Category 4 in current breast cancer despite containing no estrogen — the tumor's progesterone receptors make any systemic progestin a potential growth stimulus. This explains why the usual pattern (progestin-only safer than combined) does not hold for current breast cancer: both the estrogen and the progesterone receptor pathways are potential growth signals in a hormone receptor-positive tumor.

• Option A: Option A is incorrect because progestins are not contraindicated merely due to co-formulation with estrogen — pure progestin-only products do exist (progestin-only pill, implant, DMPA, LNG-IUD), and they are Category 4 in their own right because of progesterone receptor stimulation, not because of any estrogen content.
• Option B: Option B is incorrect because progestins are not contraindicated because they convert into estrogen — they act directly through progesterone receptors; the contraindication does not depend on conversion to estrogen.
• Option C: Option C is incorrect because the contraindication is not based on profound progestin-induced immunosuppression allowing immune escape — the mechanism is direct progesterone receptor stimulation of a hormone-sensitive tumor, not immune suppression.
• Option E: Option E is incorrect because progestins are not safe in progesterone receptor-positive tumors — on the contrary, progesterone receptor expression is precisely what makes progestins a growth risk, so progestin-only methods are contraindicated, not safe, in such tumors.

ANSWER: A

Rationale:

The copper IUD releases copper ions into the uterine cavity that are directly cytotoxic to spermatozoa, impairing sperm motility and viability and producing a local sterile inflammatory reaction in the endometrium that prevents fertilization. Critically, this mechanism is entirely non-hormonal: it does not involve estrogen or progesterone receptors and does not introduce any exogenous hormone, so it carries no risk of stimulating a hormone-sensitive tumor. This is precisely why the copper IUD is the preferred contraceptive in a woman with current hormone receptor-positive breast cancer, in whom all hormonal methods are Category 4.

• Option B: Option B is incorrect because the copper IUD does not release progesterone or any hormone — that describes the LNG-IUD; the copper IUD is non-hormonal and works by copper ion cytotoxicity.
• Option C: Option C is incorrect because the copper IUD does not produce clinically meaningful systemic copper absorption, does not suppress the hypothalamic-pituitary-ovarian axis, and does not treat breast cancer — its action is local copper ion cytotoxicity within the uterus, and it has no endocrine or antitumor effect.
• Option D: Option D is incorrect because the copper IUD does not work by physically blocking the cervix — it sits within the uterine cavity and works through copper ion effects on sperm, not by mechanical cervical obstruction.
• Option E: Option E is incorrect because copper is not converted into an estrogen — the copper IUD introduces no hormone and produces no estrogenic effect; its mechanism is non-hormonal copper ion cytotoxicity, which is exactly what makes it safe in hormone-sensitive breast cancer.

ANSWER: E

Rationale:

This question integrates the central organizing pattern of the module with its key exception. Throughout most estrogen-contraindicated conditions — prior VTE, migraine with aura, smoking over age 35, hypertension — progestin-only methods are safer because the contraindication is driven by the estrogen component, which progestin-only methods lack. Current breast cancer is the exception where this pattern collapses: because hormone receptor-positive tumors express both estrogen and progesterone receptors, both the estrogen and the progestin pathways can stimulate the tumor, making all hormonal methods Category 4. The practical implication for her is that her reliable contraceptive options are non-hormonal: the copper IUD (preferred), barrier methods, or sterilization. Recognizing both the pattern and its exception is the integrated understanding this case is designed to build.

• Option A: Option A is incorrect because progestin-only methods are not always safer than combined methods — her case is precisely the situation where they are equally contraindicated; the breast cancer guidance is not an error but a reflection of progesterone receptor biology.
• Option B: Option B is incorrect because the copper IUD is not contraindicated in breast cancer — it is the preferred option because it is non-hormonal — and progestin-only pills are not safe in current breast cancer; they are Category 4.
• Option C: Option C is incorrect because it is not true that only combined methods are ever contraindicated — in current breast cancer, progestin-only methods are also Category 4, so not all progestin-only and non-hormonal methods are universally safe (the hormonal ones are contraindicated here).
• Option D: Option D is incorrect because hormonal status is highly relevant to contraceptive choice — her hormone receptor-positive breast cancer specifically contraindicates all hormonal methods, so it is not true that any method may be used in any condition.

ANSWER: B

Rationale:

This patient has two independent features that make combined hormonal methods unsafe. A blood pressure exceeding 160 mmHg systolic or 100 mmHg diastolic is WHO MEC Category 4 — an absolute contraindication for combined methods — because ethinyl estradiol (EE) raises blood pressure (via hepatic angiotensinogen synthesis) and promotes coagulation and arterial thrombotic risk, creating an unacceptable risk of stroke and myocardial infarction in a woman whose blood pressure is already severely elevated. Her smoking at age 38 further compounds the arterial risk. The correct initial management is to decline the combined method, recommend a non-estrogen option (a progestin-only method or the copper IUD), and evaluate and manage her newly identified, untreated hypertension, which is an important finding in its own right.

• Option A: Option A is incorrect because a low 20-microgram EE dose does not offset severe hypertension and smoking — combined methods are Category 4 at her blood pressure regardless of EE dose, because even low-dose EE adds arterial thrombotic risk.
• Option C: Option C is incorrect because prescribing the combined pill and rechecking in 3 months would expose her to unacceptable arterial risk in the interim — her blood pressure already exceeds the Category 4 threshold, so the combined method should not be started at all.
• Option D: Option D is incorrect because the combined patch delivers ethinyl estradiol systemically and carries the same blood-pressure and arterial thrombotic risks as the oral pill — transdermal EE is not exempt, and the patch is also Category 4 in severe hypertension.
• Option E: Option E is incorrect because starting an antihypertensive does not immediately remove the contraindication — uncontrolled severe hypertension is Category 4, and even adequately controlled hypertension remains Category 3 for combined methods, so concurrently starting an EE-containing method is not appropriate; a non-estrogen method is the correct choice.

ANSWER: E

Rationale:

Ethinyl estradiol (EE) increases venous thromboembolism (VTE) risk through its potent first-pass hepatic estrogenic effect on the synthesis of hemostatic proteins. EE promotes hepatic synthesis of procoagulant clotting factors (including factors II, VII, VIII, and X) and reduces sensitivity to activated protein C (an endogenous anticoagulant), shifting the overall hemostatic balance toward a procoagulant state. This acquired prothrombotic shift is the mechanism by which EE-containing methods increase VTE risk, and it is why progestin-only methods, which lack EE, do not carry this venous thrombotic risk.

• Option A: Option A is incorrect because EE does not increase VTE risk by directly damaging venous endothelium through a toxic effect — its venous thrombotic effect is mediated by hepatic synthesis of coagulation factors and reduced activated protein C sensitivity, a change in the blood's procoagulant balance rather than mechanical endothelial injury.
• Option B: Option B is incorrect because EE does not lower platelet counts to cause thrombocytopenia-triggered clotting — there is no such paradoxical mechanism; EE promotes a procoagulant state through hepatic clotting factor synthesis, not through thrombocytopenia.
• Option C: Option C is incorrect because EE does not chelate calcium to activate the clotting cascade — calcium depletion would impair, not promote, coagulation, and this is not the mechanism of EE-associated VTE risk.
• Option D: Option D is incorrect because EE does affect the venous system — it increases venous thromboembolism risk through procoagulant hepatic protein synthesis; the claim that it works only on arteries and cannot increase VTE risk is contradicted by the well-established VTE risk of EE-containing methods.

ANSWER: D

Rationale:

Within the ethinyl estradiol-containing combined pill class, second-generation progestins — levonorgestrel and norgestrel — carry the lowest venous thromboembolism (VTE) risk, particularly at low EE doses such as 20 micrograms. Third-generation progestins (desogestrel, gestodene, norgestimate) and drospirenone-containing formulations are associated with approximately 1.5 to 2 times the VTE risk of levonorgestrel-containing pills, attributed to differential effects on activated protein C resistance and coagulation factor profiles. Therefore, a woman seeking the lowest VTE risk within the combined pill class should be offered a low-dose levonorgestrel formulation.

• Option A: Option A is incorrect because third-generation progestins, despite their favorable lipid and androgenic profiles, carry higher — not lower — VTE risk than second-generation levonorgestrel-containing pills; the favorable metabolic profile does not translate into lower VTE risk.
• Option B: Option B is incorrect because drospirenone-containing pills do not have the lowest VTE risk — they are associated with VTE risk comparable to or higher than third-generation formulations and higher than levonorgestrel-containing pills, and drospirenone's anti-mineralocorticoid activity does not neutralize the procoagulant effect of ethinyl estradiol.
• Option C: Option C is incorrect because progestin generation does affect VTE risk within the combined pill class — the 1.5 to 2-fold difference between second- and third-generation progestins at the same EE dose is well documented, so generation is not irrelevant.
• Option E: Option E is incorrect because first-generation progestins do not carry zero VTE risk — all EE-containing combined pills increase VTE risk above baseline, and the lowest-risk choice within the class is a low-dose second-generation levonorgestrel formulation, not a first-generation progestin assumed to be risk-free.

ANSWER: C

Rationale:

This question integrates relative versus absolute risk with the VTE risk of pregnancy to frame accurate reassurance for an eligible, healthy woman. Modern low-dose combined pills do raise relative VTE risk approximately 3 to 4-fold above the low baseline of approximately 2 per 10,000 woman-years, but the absolute excess is small — on the order of a few extra events per 10,000 woman-years. Critically, this absolute risk remains substantially lower than the VTE risk of pregnancy itself (approximately 29 per 10,000 pregnancies). So for an eligible healthy woman without contraindications, the absolute VTE risk of a combined pill is small, and the protection it provides against pregnancy-associated VTE is a relevant counterbalance. This calibrated framing — acknowledging the real relative increase while placing it in absolute context against the alternative of pregnancy — is the accurate way to reassure her sister.

• Option A: Option A is incorrect because avoiding all contraception is not the lower-risk path — pregnancy carries a higher absolute VTE risk than a modern low-dose combined pill, so for an eligible healthy woman the pill is not more dangerous than the alternative of pregnancy.
• Option B: Option B is incorrect because modern low-dose combined pills do not raise VTE risk 20 to 30-fold — the correct figure is approximately 3 to 4-fold above baseline; a 20 to 30-fold increase is not accurate, so her fear should be recalibrated rather than confirmed.
• Option D: Option D is incorrect because VTE risk from combined pills is not confined to women with thrombophilia — all EE-containing pills raise VTE risk above baseline even in women without a clotting disorder; thrombophilia amplifies the risk further but is not the only source of it.
• Option E: Option E is incorrect because the pill does not eliminate VTE risk — it raises it modestly in absolute terms; the accurate reassurance is that the absolute risk is small and lower than pregnancy's, not that the pill is risk-free.